Search - tctmd.com

Displaying 1 - 20 of 128

Sort: Relevancy | Date

News Daily News

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

Yael L. Maxwell

December 06, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Daily News

Periprocedural MI Predicts Mortality After PCI for Chronic Total Occlusion

L.A. McKeown

November 10, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Presenter: Gregg W. Stone, Ron Waksman, John A. Ambrose

November 01, 2016

Presentation TCT 2016

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Presenter: Gregg W. Stone, Ron Waksman, Jonathan Leor

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Presenter: Gregg W. Stone, Ron Waksman, Seung-Jung Park

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Presenter: Gregg W. Stone, Ron Waksman, Vasim Farooq

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Case Introduction: How Would You Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Announcing the NIH-sponsored HYBRID Revascularization Trial

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

Presenter: John D. Puskas, Gregg W. Stone, John S. Douglas Jr

November 01, 2016

Presentation TCT 2016

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

Presenter: Cindy L. Grines, Holger Thiele, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

EXCEL Top Line Results Revisited

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Gregg W. Stone

October 31, 2016

Advertisement

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Periprocedural MI Predicts Mortality After PCI for Chronic Total Occlusion

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

FDA Perspectives on Short DAPT IDE Trials

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Case Conclusion: How Did We Revascularize This Patient?

Case Introduction: How Would You Revascularize This Patient?

Announcing the NIH-sponsored HYBRID Revascularization Trial

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

EXCEL Top Line Results Revisited

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content